Advertisement

A Pharmacokinetic Approach to the Treatment of Depression

  • Folke Sjöqvist

Abstract

Treatment with standard doses of the tricyclic antidepressants nortriptyline (NT) and desmethylimipramine (DMI) results in 10- to 30-fold interindividual differences in their steady-state plasma concentrations (Hammer and Sjöqvist, 1967a; Alexanderson and Sjöqvist, 1971).

Keywords

Single Oral Dose Plasma Clearance Multiple Oral Dose Endogenous Depression Pharmacokinetic Approach 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexanderson, B., Evans, D. A. P., and Sjöqvist, F., 1969, “Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy,” Brit. Med. J. 4: 764–768.PubMedCrossRefGoogle Scholar
  2. Alexanderson, B., and Sjöqvist, F., 1971, “Individual differences in the pharmacokinetics of monomethylated tricyclic antidepressants: Role of genetic and environmental factors and clinical importance,” Ann. N. Y. Acad. Sci. 179: 739–751.PubMedCrossRefGoogle Scholar
  3. Alexanderson, B., 1972a, “Pharmacokinetics of nortriptyline in man after single and multiple oral doses: The predictability of steady-state plasma concentrations from single dose plasma-level data,” European. J. Clin. Pharmacol. 4: 82–91.CrossRefGoogle Scholar
  4. Alexanderson, B., 1972b, On interindividual variability in plasma levels of nortriptyline and desmethylimipramine in man: A pharmacokinetic and genetic study, Linköping University Medical Dissertations No. 6.Google Scholar
  5. Alexanderson, B., 1972c, “Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses—a cross-over study,” European J. Clin. Pharmacol. 5: 1–10.CrossRefGoogle Scholar
  6. Alexanderson, B., 1973, “Prediction of Steady-State Plasma Levels of Nortriptyline from Single Oral Dose Kinetics: A Study in Twins,” European J. Clin. Pharmacol. 6: 44–53.CrossRefGoogle Scholar
  7. Alexanderson, B., and Borgå, O., 1973, “Urinary Excretion of Nortriptyline and Five of its Metabolites in Man after Single and Multiple Oral Doses,” European J. Clin. Pharmacol. 5: 174–180.CrossRefGoogle Scholar
  8. Alexanderson, B., Borgå, O., and Alvan, G., 1973, “The Availability of Orally Administered Nortriptyline,” European J. Clin. Pharmacol. 5: 181–185.CrossRefGoogle Scholar
  9. Åsberg, M., Cronholm, B., Sjöqvist, F., and Tuck, D., 1970, “The correlation of subjective side effects with plasma concentrations of nortriptyline,” Brit. Med. J. 4: 18–21.PubMedCrossRefGoogle Scholar
  10. Åsberg, M., Cronholm, B., Sjöqvist, F., and Tuck, D., 1971a, “Relationship between plasma level and therapeutic effect of nortriptyline,” Brit. Med. J. 3: 331–334.PubMedCrossRefGoogle Scholar
  11. Åsberg, M., Evans, D. A. P., and Sjöqvist, F., 1971b, “Genetic Control of nortriptyline kinetics in man: A study of the relatives of propositi with high plasma concentration,” J. Med. Genet. 8: 129–135.PubMedCrossRefGoogle Scholar
  12. Åsberg, M., and Germanis, M., 1972, “Ophthalmological effects of nortriptyline-relationship to plasma level,” Pharmacology 7: 349–356.PubMedCrossRefGoogle Scholar
  13. Borgå, O., Hamberger, B., Malmfors, T., and Sjöqvist, F., 1970, “The role of plasma protein binding in the inhibitory effect of nortriptyline on the neuronal uptake of norepinephrine,” Clin. Pharm. Therap. 11: 581–588.PubMedGoogle Scholar
  14. Braithwaite, R. A., Goulding, R., Theano, G., Bailey, J., and Coppen, A., 1972, “Plasma concentration of amitriptyline and clinical response,” Lancet 1: 1297–1300.PubMedCrossRefGoogle Scholar
  15. Freyschuss, U., Sjöqvist, F., and Tuck, D., 1971, “Tyramine pressor effects in man before and during treatment with nortriptyline or ECT: Correlation between pharmacokinetics and effect of nortriptyline,” Pharmacol. Clin. 2: 72–78.CrossRefGoogle Scholar
  16. Hamberger, B., and Tuck, D., 1973, “Effect of Tricyclic Antidepressants on Uptake of Noradrenaline and 5-hydroxytryptamine into Rat Brain Slices Incubated in Buffer of Human Plasma,” European J. Clin. Pharmacol. 6: 1–7.CrossRefGoogle Scholar
  17. Hammer, W., and Sjöqvist, F., 1967a, “Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds,” Life Sci. 6: 1895–1903.PubMedCrossRefGoogle Scholar
  18. Hammer, W., Ideström, C. M., and Sjöqvist, S., 1967b, “Chemical control of antidepressant drug therapy,” In Proceedings of the First International Symposium on Antidepressant Drugs. Milano, 1966, Ed. by S. Garattini and M. N. G. Dukes, Excerpta Med. Intern. Congr. Ser. No. 122: 301–310.Google Scholar
  19. Hammer, W., Mårtens, S., and Sjöqvist, F., 1969, A comparative study of the metabolism of desmethylimipramine, nortriptyline and oxyphenylbutazone in man. Clin. Pharmacol. Therap. 10: 44–49.Google Scholar
  20. Kragh-Sørensen, P., Eggert-Hansen, C., and Åsberg, M., 1973, Plasma levels of nortriptyline in the treatment of endogenous depression. I: 113–115.Google Scholar

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • Folke Sjöqvist
    • 1
  1. 1.Department of Clinical PharmacologyKarolinska InstitutetStockholmSweden

Personalised recommendations